Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01130532 · ClinicalTrials.gov registry record · Phase 4
A Study in Erectile Dysfunction
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 623
- Enrollment target
NCT01130532 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 623 participants.
The verdict
NCT01130532, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 623 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate if treatment with tadalafil once daily will allow men to return to normal erectile function in those who did not have normal erectile function following as-needed (PRN) Phosphodiesterase Type 5 (PDE5) Inhibitor treatment.
Interventions
- DRUG Placebo
- DRUG Tadalafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 623 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01130532
The ClinicalTrials.gov registry entry for NCT01130532 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 623 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01130532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01130532 about?
NCT01130532 is a clinical study titled "A Study in Erectile Dysfunction". The purpose of this trial is to evaluate if treatment with tadalafil once daily will allow men to return to normal erectile function in those who did not have normal erectile function following as-needed (PRN) Phosphodiesterase Type 5 (PDE5) Inhibitor treatment.
What is the current status of trial NCT01130532?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 623 participants. The study started on 2010-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01130532?
The interventions under investigation include: Placebo (DRUG), Tadalafil (DRUG).
Who is sponsoring clinical trial NCT01130532?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.